UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma
Voxtalisib, is a specific, effective, and reversible dual inhibitor, which inhibits both pan-class I phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). To date, voxtalisib has been studied in trials for melanoma, lymphoma, glioblastoma, breast cancer, and other cancers. In...
| Автори: | , , , , , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Frontiers Media S.A.
2022-06-01
|
| Серія: | Frontiers in Pharmacology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fphar.2022.914733/full |